The typical Hexarelin researcher is a more advanced lifter or peptide-experienced adult who has already cycled the cleaner GHRPs, knows the receptor desensitization risk, and wants either a short maximum-amplitude pulse or is reading the CD36 cardiac literature. They are not running it daily for months. They are running it in deliberate 2-week windows.
Hexarelin is a synthetic hexapeptide developed in the 1990s, modeled directly on GHRP-6with a single amino acid substitution that increased potency dramatically. Per microgram, it produces the largest GH pulse of any GHRP. That potency is the reason researchers reach for it. It is also the reason the receptor desensitizes faster than on any other GHRP and protocols stay short.
What Hexarelin actually is
Sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. Molecular weight 887 Daltons. The 2-methyl modification on tryptophan is what bumps the potency above GHRP-6's, and the same modification is what locks the molecule onto the receptor for longer per binding event. That extended occupancy is the foundation of both the potency and the desensitization problem.
The mechanism in plain English
Hexarelin binds GHSR-1a on the anterior pituitary with high affinity, triggering a strong GH pulse. It also binds CD36, a scavenger receptor expressed on cardiac and macrophage tissue. The cardiac binding is independent of the GH effect and is the foundation of the separate cardioprotective research file. No other GHRP in standard research use has this secondary receptor profile at the same magnitude.
Why 2-week cycles, not 12-week
Receptor desensitization is the limiting factor. By the end of week 2 of daily dosing at standard research doses, the GH pulse amplitude on the same dose drops measurably. By week 4 it may be a fraction of the week-1 response. The receptor protects itself by downregulating. The standard Hexarelin protocol respects this and runs short pulse cycles (typically 14 days on, 14 days off, or shorter) so the receptor has time to repopulate.
Quick reference table
| Spec | Value | Note |
|---|---|---|
| Sequence | His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2 | Hexapeptide, ~887 Da |
| Receptors bound | GHSR-1a (pituitary), CD36 (cardiac) | Unique among GHRPs |
| Standard dose | 100 mcg subq, 1 to 2x daily | Lower than other GHRPs by mass |
| Per-dose GH amplitude | 5 to 10x Ipamorelin at equimolar | Largest pulse in the GHRP class |
| Cycle window | 2 weeks on, 2 weeks off | Some protocols run 14 days, then 28 days off |
| Secondary file | CD36-mediated cardioprotection | Preclinical and small clinical signal |
What Hexarelin researchers track
Acute GH response (one-time blood draw 30 to 60 minutes post-dose at week 1, compared to a repeat at week 2) is the marker that confirms the receptor is still responding. Body composition response in a 2-week window is small and not the primary tracking goal for such a short cycle. Researchers reading the cardiac side of the file watch cardiac biomarkers (NT-proBNP, troponin), though most do not have these accessible. AM cortisol is worth tracking as with the other older GHRPs.
The CD36 cardioprotection file
Hexarelin's binding to CD36 on cardiac tissue has been documented to reduce infarct size in ischemia-reperfusion rodent models, improve ventricular function in heart failure models, and reduce inflammation in atherosclerotic plaque models. Small human studies have shown modest improvements in cardiac function on Hexarelin in heart failure patients, independent of GH effect. This is not clinical practice. It is a research file with consistent enough preclinical signal to remain active.
Compared to Ipamorelin
Hexarelin gives a much larger per-dose GH pulse. Ipamorelin gives a much longer usable cycle. Hexarelin raises cortisol and prolactin. Ipamorelin does not. Hexarelin uniquely binds CD36; Ipamorelin does not. For long-running general protocols, Ipamorelin is the right tool. For short amplitude pulses or for researchers reading the cardiac file, Hexarelin earns the slot.
External authority and source reading
The Mediolanum Farmaceutici group in Milan published the original Hexarelin pharmacology and clinical development work in the 1990s. The CD36 binding and cardioprotective research has been led by the Ong, Sato, and Locatelli groups across Canada, Japan, and Italy, with publications in Endocrinology, Circulation Research, and the Journal of Endocrinology spanning the last 20 years.
Compliance frame
Hexarelin is not FDA-approved. It is sold in the US as research-use-only material for in-vitro and laboratory study. Aion ships Hexarelin with research-grade labeling and a third-party COA. Any decision about your own use is a conversation for a qualified clinician familiar with peptide research.
Bottom line
Hexarelin is the strongest GHRP and the one with the most documented secondary biology. It buys both with the shortest usable cycle in the class. Run it in 2-week pulses, respect the receptor desensitization, and pay attention to the cardiac file if that is your read.